BRISTOL DROXIA DECREASES MEDIAN ANNUAL SICKLE CELL CRISES BY 46%, TRANSFUSIONS BY 37%; LABELING WILL STRESS BI-WEEKLY BLOOD MONITORING FOR NEUTROPENIA

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".